Frequency of the mdr-1 C>;T gene polymorphism in patients with COPD by Dogan, Ömer Tamer et al.
CLINICAL SCIENCE
Frequency of the mdr-1 C.T gene polymorphism in
patients with COPD
O¨mer Tamer Dogan,I Nurkay Katrancıoglu,II Og˘uz Karahan,II Gu¨lizar Canan Sanlı,I Ali Zorlu,III
S¸inasi ManduzII
I Department of Chest Diseases, Medical Faculty of Cumhuriyet University, Sivas, Turkey. II Department of Cardiovascular Surgery, Medical Faculty of
Cumhuriyet University, Sivas, Turkey. III Department of Cardiology, Faculty of Medicine of Cumhuriyet University, Sivas, Turkey.
BACKGROUND AND AIM: The multi-drug resistant-1 (MDR-1) gene is located on human chromosome 7 and encodes
a glycosylated membrane protein that is a member of the ATP-binding cassette transporters superfamily. The aim of
the study was to reveal the role of the C3435T MDR-1 gene polymorphism in chronic obstructive pulmonary disease.
METHOD: DNA samples from 41 patients with chronic obstructive pulmonary disease and 50 healthy control
participants were used to compare MDR-1 gene profiles. Genotyping assays were performed using the StripAssay
technique that is based on reverse-hybridization.
RESULTS: The T allele polymorphism in the MDR-1 gene located at position 3435 in exon 26 was shown to correlate
with chronic obstructive pulmonary disease.
CONCLUSION: These preliminary results suggest that the T allele polymorphism of the MDR-1 gene is associated
with chronic obstructive pulmonary disease.
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INTRODUCTION
Increasing evidence suggests that pulmonary and sys-
temic inflammatory processes play an important role in
the development and progression of chronic obstructive
pulmonary disease (COPD), which is characterized by
partially reversible airway obstruction.1 Genetic factors,
in addition to oxidative stress factors (e.g., smoking),
have also been implicated in the development of this
disease.2
The underlying genetic causes have been evaluated in
several studies to clarify the etiopathogenesis of the
systemic effects of COPD. The molecular basis of inflamma-
tion in COPD has also been investigated.3 In addition,
studies have addressed the protective genetic factors that
combat oxidant damage, which is caused by smoke and
related agents. It has been suggested that multidrug
resistance (MDR) proteins may protect lung tissue from
oxidative stress by acting as anti-oxidants.4 MDR genes
constitute a class of genes that play a crucial role in multiple
drug resistance in eukaryotic cells. The MDR-1 gene
encodes P-glycoprotein (P-gp), which plays a role in the
active transport of various substrates. More specifically, P-
gp plays an important role in the excretion of toxic
substances, ingestion of nutrients, transport of ions and
peptides, and transduction of cellular signals. Notably, it is
an adenosine triphosphate (ATP)-dependent transport
protein. P-gp carries free cholesterol from the plasma
membrane to the endoplasmic reticulum, where cholesterol
esterification occurs.5-7 The single nucleotide polymorphism
(SNP) C3435T located in exon 26 of the MDR-1 gene results
in decreased expression of P-gp.
In the present study, we aimed to evaluate the relation-
ship between COPD and the MDR-1 gene, which has been
postulated to play a role in the inflammatory process and
protection against oxidative stress.
MATERIALS AND METHODS
Ninety-one participants were selected for this study. Of
these, forty-one were diagnosed with COPD (i.e., emphy-
sema) and comprised the study group. The remaining fifty
participants were healthy control participants. The clinical
diagnosis of COPD was made by a computed tomography
(CT) scan. Participants with additional systemic disorders
were excluded from the study. After informed consent was
obtained, a 5-ml peripheral blood sample was taken from
each participant for genetic analysis.
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Polymorphism Analysis:
Total genomic DNA was extracted from 100-ml blood
samples using the Invitek kit (Invitek, Invisorb spin blood,
Germany). The MDR-1 gene was amplified in a biotin-
labeled single multiplex amplification reaction and evalu-
ated for the 3435 C.T polymorphism. Polymerase chain
reaction (PCR) was performed in a Perkin Elmer Geneamp
9600 Thermal Cycler. The protocol consisted of an initial
melting step of 2 minutes at 94 C˚, followed by 35 cycles of 15
seconds at 94 C˚, 30 seconds at 58 C˚ and 30 seconds at 72 C˚,
and a final elongation step of 3 minutes at 72 C˚.
Polymorphism analysis was performed using the Strip
Assay technique (Vienna Lab, PGX-HIV Strip Assay
GmbH, Austria), which is based on reverse-hybridization.
Data from the study population and the healthy control
group were statistically analyzed using the SPSS software
program (SPSS Inc. Chicago, IL, USA). P,0.05 was
considered to indicate statistical significance.
RESULTS
The study group was composed of 24 males (59%) and 17
females (41%); the control group was composed of 29 males
(58%) and 21 females (42%). The mean age of the study
group was 62.3¡7.3 years and that of the healthy control
participants was 57.8¡12.4 years. Thirty-five (85%) and
thirty-one (62%) of the study and the control participants,
respectively, had a history of smoking.
MDR-1 CC (wild type), CT (heterozygous) and TT
(homozygous) gene polymorphisms were compared
between the study and control groups. The wild type,
heterozygous, and homozygous gene polymorphisms were
found in 9 (22%), 21 (51%), and 11 (27%) of the study
participants, respectively. In the control group, the wild
type, heterozygous, and homozygous gene polymorphisms
were found in 35 (70%), 11 (22%), and 4 (8%) participants,
respectively (Table 1).
This comparison showed that both MDR-1 homozygous
and heterozygous polymorphisms were significantly more
frequent in patients with COPD (p,0.05).
DISCUSSION
COPD can lead to death and is the fourth most frequent
cause of death in Europe and the United States.8 It is
important to clearly elucidate the etiopathogenesis of this
disease to prevent death in patients and to develop new
therapeutic modalities. There is increasing evidence that
indicates that the inflammatory process in COPD patients is
activated (e.g., an increase in circulatory cytokines, chemo-
kines, and acute phase reactants, particularly during
exacerbation and progression of the disease).1,9,10
Smoking, in addition to genetic and other environmental
factors, contributes to the development of COPD. Smoking
overworks the detoxification system by causing an imbal-
ance within the protease-anti-protease system. Various
studies have assessed the molecular mechanisms of these
systems.11 The MDR-1 gene, which is located on chromo-
some 7, encodes P-gp, a transmembrane efflux pump that
transports drugs and toxins from the intracellular to the
extracellular domain. The C3435T single nucleotide poly-
morphism located in exon 26 of the MDR1 gene was
recently shown to be associated with P-gp levels and
substrate uptake. Individuals who were homozygous for
the T-allele had a significantly decreased P-gp expression
level compared to those homozygous for the C-allele.
Previous literature has shown that the MDR-1 3435 C.T
polymorphism may be important in Parkinson disease,
inflammatory bowel diseases, cerebral artery aneurisms,
refractory epilepsy, and cluster of differentiation 4 (CD4)
cell regeneration during HIV (Human Immunodeficiency
Virus) infection. It has also been shown to influence drug
levels in the body. 7,12,13 In other studies, it was suggested
that P-gp protein plays a role in combating the toxic effects
of smoking and in the removal of oxidative stress
metabolites.14,15 The gene has also been shown to play a
role in cellular regeneration.16 In a study by van der Deen et
al., MDR proteins were shown to exhibit a protective effect
against oxidative stress and that COPD patients have
decreased levels of Multidrug resistance-associated
protein-1 (MRP-1) in their bronchial epithelium4. It has
also been established that pro-inflammatory cytokines
decrease the amount of products (e.g. MRP-1) secreted
from the cell by P-gp.17 In other studies, a decrease in P-gp
expression and activity was observed during inflamma-
tion.18 Similarly, decreased expression of P-gp has been
shown in individuals with the MDR1 polymorphism.12 In
the present study, we investigated the MDR-1 3435 C.T
polymorphism in COPD patients. In the study group, the
wild type, heterozygous, and homozygous MDR1 gene
polymorphisms were found in 9 (22%), 21 (51%), and 11
(27%) of the participants, respectively, whereas in the
control group, they were found in 35 (70%), 11 (22%), and
4 (8%) of the participants. These results indicate a distribu-
tion of the C/C, T/T, and C/T genotypes in patients with
COPD of 22%, 51%, and 27%, respectively. The T-allele
frequency was significantly higher (P , 0.05) in COPD
patients when compared to the healthy control participants
(52% and 19%, respectively), (Tables I and II).
This pilot study had some limitations due to its retro-
spective nature. Specifically, the phenotypic reflection of the
Table 1 - Distribution of MDR-1 (P-glycoprotein,
ATP-binding cassette ABC superfamily of membrane
transporters) genotypes in patients with COPD and
healthy control participants.
Group
Genotype
Total
CC
(Wild Type)
CT
(Heterozygous)
TT
(Homozygous)
COPD n (%) 9 (22%) 21 (51%) 11 (27%) 41 (100%)
Control n (%) 35 (70%) 11 (22%) 4 (8%) 50 (100%)
p* 0.000 0.004 0.016
*p, 0.05
Table 2 - Allelic frequency of the MDR-1 gene
(P-glycoprotein, ATP-binding cassette ABC superfamily
of membrane transporters) C3435T polymorphism in
patients with COPD and healthy control participants.
Group
Allele
TotalC T
COPD n (%) 39 (48%) 43 (52%) 82 (100%)
Control n (%) 81 (81%) 19 (19%) 100 (100%)
p* 0.000 0.000
*p, 0.05
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resulting genotype distribution was not assessed. In addi-
tion, neither P-gp nor MRP-1 levels were evaluated.
However, the primary purpose of this study was to obtain
a genetic reference for future studies by assessing a limited
population. Thus, our investigation focused on evaluating
the different MDR-1 gene polymorphisms.
Our results show that the CT and TT MDR-1 gene
polymorphisms were significantly more frequent in COPD
patients. These findings suggest that MDR-1 may play a role
in the development of COPD through some inflammatory
and detoxification mechanisms.
More detailed studies focusing on phenotypic alterations
are necessary to clarify our findings. In addition, elucidating
the molecular etiopathogenesis of COPD should open new
frontiers in identifying populations at risk and in develop-
ing new treatment and follow-up modalities.
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